JPRN-jRCT2031260211 Esketamine Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines JPRN-jRCT2031260211 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 7 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2031260211 is a hot trial to watch
Depressive Disorder, Major is being segmented by mechanism, treatment setting, geography and endpoint architecture. JPRN-jRCT2031260211 is notable because it evaluates Esketamine Hydrochloride in a Phase 3 design sponsored by Janssen Pharmaceuticals, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2031260211 |
| Official title | A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression |
| Phase / status | Phase 3 / 募集前 |
| Intervention | Esketamine Hydrochloride |
| Sponsor | Janssen Pharmaceuticals, Inc. |
| Geography | Japan |
| Enrollment | [object Object] |
| Primary endpoint | 1.二重盲検（DB)投与期： Montgomery Asbergうつ病評価尺度（MADRS）総スコアの，Day 1から4週間の二重盲検投与期終了時までの変化 MADRSは，うつ病の重症度を測定し，抗うつ薬投与による変化を検知するための，臨床評価者による評価尺度である。この検査は10項目から成り，各項目を0（症状なし，又は正常）から6（重度）までのスコアで評価し，総スコアの最高スコアは60である。スコアが高いほど，疾患が重症であることを示す。 評価期間：ベースライン（Day 1[ランダム化前]）から4週間の二重盲検投与期終了時（Day 28）まで |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Esketamine Hydrochloride in Depressive Disorder, Major.
Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across Japan shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- 1.二重盲検（DB)投与期： Montgomery Asbergうつ病評価尺度（MADRS）総スコアの，Day 1から4週間の二重盲検投与期終了時までの変化 MADRSは，うつ病の重症度を測定し，抗うつ薬投与による変化を検知するための，臨床評価者による評価尺度である。この検査は10項目から成り，各項目を0（症状なし，又は正常）から6（重度）までのスコアで評価し，総スコアの最高スコアは60である。スコアが高いほど，疾患が重症であることを示す。 評価期間：ベースライン（Day 1[ランダム化前]）から4週間の二重盲検投与期終了時（Day 28）まで (time frame not reported)
- 1. Double-Blind (DB) Treatment Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 to the End of the 4-Week Double-Blind Treatment Phase The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. Time frame: Baseline (Day 1 [prerandomization]) up to end of the 4-Week DB treatment phase (Day 28) (time frame not reported)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Esketamine Hydrochloride is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Janssen Pharmaceuticals, Inc. is resolved to a normalized organization record in HUNTERDON COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
JPRN-jRCT2031260211 provides a focused lens on Depressive Disorder, Major development. Its value will be determined by whether Esketamine Hydrochloride can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
